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Abstract
Rationale Rodents are usually used to assess the ability of
antipsychotic drugs to antagonize hyperlocomotion induced
by dopamine agonists, such as the psychostimulant
d-amphetamine. However, the substantial differences
between rodents and humans may hinder extrapolation of
experimental results to humans. For this reason, we
speculated that Göttingen miniature pigs, which show
strong physiological and genetic homology with humans,
might be a better model for investigating the effects of
antipsychotics. To investigate this, we determined whether
d-amphetamine induced hyperlocomotion in miniature pigs
and whether this effect was reversible by antipsychotics.
Materials and methods d-Amphetamine was tested in
the dose range of 0.2 to 2.0 mg kg−1 for its ability to
induce hyperactivity in the open field, and the effects of
two antipsychotics, haloperidol and risperidone, on
amphetamine-induced hyperactivity were examined.
Results d-Amphetamine increased open-field activity at
0.2, 0.4, and 0.7 mg kg−1 s.c. but not at higher doses. The
stimulation of open-field activity induced by 0.4 mg kg−1
s.c. d-Amphetamine was antagonized by haloperidol and
risperidone (0.01 and 0.04 mg kg−1 s.c.).
Conclusion d-Amphetamine-induced hyperlocomotion in
miniature pigs may be a useful model for studying the
effect of putative antipsychotics.
Keywords Locomotor activity . Open field . Amphetamine .
Antipsychotic . Haloperidol . Risperidone
Introduction
Schizophrenia is a debilitating psychiatric disorder that affects
about 1% of the population worldwide (Jablensky et al. 1992).
No single treatment alleviates its symptoms, which include
psychosis, flattened affect, social withdrawal, and cognitive
dysfunction. Although the precise cause of schizophrenia
remains unknown, it is established that the dopaminergic
system is involved (Björklund and Dunnett 2007; Feather-
stone et al. 2007; Iversen and Iversen 2007). Indeed, one of
the most commonly used methods to screen drugs for
antipsychotic-like activity is the ability of a compound to
reverse hyperlocomotion caused by dopamine agonists such
as amphetamine or apomorphine (Björklund and Dunnett
2007; Higgins 1998; Iversen and Iversen 2007; Weiner et al.
2000). The so-called typical antipsychotics are dopamine
D2 receptor antagonists and include drugs such as
perphenazine and haloperidol, while atypical antipsy-
chotics act at a number of receptors, including the
dopamine D2 receptor and the serotonin 5HT2A receptor.
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The hyperlocomotion elicited by amphetamine in rats is
reversed by both typical and atypical antipsychotics
(Geyer and Ellenbroek 2003).
A commonly used rodent model for testing antipsychotic
activity is the reversal of dopamine agonist-induced hyper-
locomotion. However, while such a model can help
elucidate the fundamental mechanisms of disease processes,
the phylogenetic distance between rodents and humans
makes extrapolation of findings from rats to humans
problematic. In contrast, pigs show a strong homology
with humans, having a similar physiology, which has led to
their use in toxicological research (Svendsen 2006). The
pharmacokinetics of a number of drugs, including those
administered by the subcutaneous route, are very similar in
pigs and humans (Larsen and Rolin 2004). Furthermore, the
sequence and chromosome structure of the pig genome
shows strong similarity to that of humans (Chen et al. 2007;
Lunney 2007; Schook 2007). These similarities mean that
pigs could bridge the gap between rodent preclinical
research and human clinical studies.
The impracticality of using large animal models in
biomedical research (for example, housing, amount of test
compound needed, handling) led to the development of the
miniature pig (minipig), which is about 25% the size of a
“regular” pig, as laboratory animal (e.g., Chapret et al.
1973; Tumbleson 1986). The advantages of the smaller
animal have raised interest in its use as animal model to aid
the transition from preclinical to clinical studies (de Groot
et al. 2005; Lind et al. 2007; Nunoya et al. 2007; Vodička et
al. 2005). Indeed, the minipig, which displays a greater
pharmacological similarity to humans than do rodents, is
expected to provide a useful animal model for assessing the
efficacy and adverse effects of psychoactive agents, such as
antipsychotics (e.g., reviewed by Elman et al. 2006;
Haddad and Wieck 2004; Jin et al. 2004), and may lead to
the identification of side effects not seen in rodent models.
This is important because in the past the development of
several second-generation antipsychotics was terminated
because the drugs had unacceptable side effects in humans
(e.g., on the heart and on cholesterol levels), side effects that
were not detected during preclinical testing with rodents. Of
course, it remains to be established whether such side effects
will be seen in minipigs.
Recently, it was shown that d-amphetamine evokes
dopamine release (Lind et al. 2005a, b) and hyperlocomotion
in pigs in an open-field (OF) test (Lind et al. 2005a; Terlouw
et al. 1992), similar to the effects of d-amphetamine in
rodents. This raises the possibility of using pigs to
evaluate the antipsychotic-like actions of compounds.
The present study was designed to replicate previous
findings regarding the behavioral responses of Göttingen
minipigs elicited by d-amphetamine (Lind et al. 2005a;
Terlouw et al. 1992) and to investigate the effect of the
typical antipsychotic haloperidol and the atypical antipsychotic
risperidone on these responses. A series of four experiments
was performed (see Fig. 1) for the following reasons:
1. To determine the lowest dose of d-amphetamine that
reliably induces behavioral activation in Göttingen
minipigs in the OF test without eliciting overt non-
locomotor effects (experiments 1 and 2)
2. To assess the reproducibility of OF behavior in minipigs
3. To assess the ability of two clinically relevant
antipsychotics—haloperidol (experiment 3) and
risperidone (experiment 4)—to antagonize the d-
amphetamine-induced behavioral activation
Materials and methods
Animals
Twenty-four male Göttingen minipigs aged 34–37 weeks
(mean 36 weeks) on arrival at our animal facilities were
supplied by Ellegaard (Ellegaard Göttingen Miniature pigs
ApS, Dalmose, Denmark). All boars were housed individ-
ually in two rows of 12 pens, each measuring 80×100 cm.
The pens were aligned along a central corridor. The back
wall of the pens was made of galvanized steel wire mesh
(aperture 7 cm). The lower parts of the walls between
adjacent pens were made of plastic-coated steel grids to a
height of 50 cm; the upper part, to a height of 75 cm, was
made of waterproof triplex. The animals could see each
other. The front wall consisted of waterproof triplex, mea-
suring 80 (width)×85 (height) cm with a door (60 cm×
55 cm), above a 20-cm high threshold. All pens were
covered with a grating to prevent the pigs from escaping.
Each pen was provided with a food and water dispenser
(GROBA Feeding System, Wijchen, The Netherlands). The
concrete floor was partially covered with a rubber mat
mulched with sawdust as bedding. Environmental enrichment
was provided by pieces of wood or chains for biting and
chewing and a plastic bucket to play with. The minipigs were
kept under a controlled light cycle, lights being on from 0700
to 1900. All animals were fed approximately 220 g of chow
(ssniff® complete feeds for minipigs, supplier: ssniff,
Borchen, Germany), supplemented with a handful of grass
pellets (supplier: Waaiboerhoeve, Wageningen University and
Research Center, Lelystad, The Netherlands) and half an apple
twice daily (approximately at 830 and 1500). Tap water was
always available ad libitum. All animals were acclimatized to
the facility for 1 week after delivery, after which they were
habituated to handling and subcutaneous injections of saline.
They were exposed to the OF in10-min sessions once daily on
five successive days.
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Twenty-four minipigs were assigned to one of three
experimental groups, using a random-matched assignment
procedure (SAS PLAN Procedure; SAS Institute Inc., Cary,
NC, USA) with body mass as matching variable, with the
restriction that pigs from the same litter were assigned to
different groups (Table 1).
Apparatus
Two identical OFs, each measuring 230 cm×340 cm,
were used. They were arranged side by side in a room
adjacent to the animal vivarium. The side walls were
approximately 125 cm high and made of black water-
proof triplex. The right side wall of the right OF and the
back walls of both OFs were placed against the walls of
the experimental room. The floor consisted of concrete,
covered with black rubber mats. A video camera was
mounted in the center above the right side wall of the
left OF and above the left side wall of the right OF, at a
height of approximately 2.5 m.
Procedure
Registration of behavior OF behavior was recorded in
1-h test sessions, using two time-coded Sanyo TLS-9024PA
video recorders and analyzed with the video-tracking system
EthoVision Color Pro (Version 3.1, Noldus, Wageningen,
The Netherlands; Noldus et al. 2001; Spink et al. 2001),
using MPEG1-files converted from videotapes recorded with
a with CanopusMPEGPRO
EMR
EMR100 digital video recorder,
running MEDIACRUISE application software, or on-line via
a Piccolo video-grabber card. Sampling speed was set to
5 frames s−1. In addition, in experiment 1, the videotaped
behavior of the minipigs during the first 2 min of each of the
six successive 10-min blocks of a test session was scored,
using an ethogram published by Lind et al. (2005a),
extended with the following behaviors: running, jumping,
lying, tail wagging, and non-forward locomotion These
behaviors and any behavior that was not part of the
predefined ethogram were registered using The Observer
software (Observer XT, Noldus) by a highly experienced
technician. The frequency and duration of these behaviors
were recorded.
Test compounds
d-Amphetamine was obtained from BUFA b.v. (Uitgeest,
The Netherlands) and dissolved in 0.9% NaCl solution
(pH of solution 5.1). Haloperidol and risperidone were
obtained from Johnson & Johnson, Pharmaceutical
Research & Development (Beerse, Belgium). Haloperidol
was dissolved in H2O+1H2T (pH of solution 4), and
risperidone was dissolved in H2O+2H2T (pH of solution
4.08). The solvents of the respective drugs served as
vehicle control solutions.
Ethical approval
The study was reviewed and approved by the local ethics
committee (DEC, dierexperimentele commissie) under
number 2006177.b and was conducted in accordance with
the recommendations of the EU directive 86/609/EEC. All
efforts were taken to minimize the number of animals used
and their suffering.
Experiment 1: Assessment of the effects of 0.4, 0.7, 1,
and 2 mg kg−1 d-amphetamine on OF behavior
Procedure Two pigs (the second heaviest and the second
lightest one) were selected from each of the three groups of
pigs for the first dose-finding study (n=6, see Table 1). The
minipigs were then about 40 weeks old. Vehicle (0.9%
NaCl solution) or d-amphetamine was injected s.c. in a
volume of 0.05 ml kg−1 body mass (in the order vehicle,
0.4, 0.7, and 1.0 mg kg−1 d-amphetamine, vehicle,
2.0 mg kg−1 d-amphetamine), and the OF session was
started directly afterwards. Two minipigs were tested in
parallel, i.e., three series of two pigs were tested per day.
There was minimally a 3-day washout period between
successive test sessions.
Fig. 1 The two phases of
the study and the average age
(in weeks) of the minipigs at the
start of the adaptation period
and of the subsequent
experiments
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Statistical analysis The behavior of the minipigs in the OF
was analyzed using EthoVision per 20 min intervals. The
following parameters were calculated: distance moved
(centimeter), mean velocity (centimeter per second), bouts
of moving (i.e., frequency of moving), total duration of
moving (second), and mean duration of moving per bout
(second). The start and stop threshold values used for
discriminating movement from immobility with EthoVision
were determined from a plot of the velocities (expressed as
centimeter per second) per sample (0.2 s; EthoVision
settings: start velocity 30, stop velocity 10, no input filter).
The reproducibility of the OF results was assessed by
comparing the behavior of the pigs in the two vehicle
sessions by a repeated measures analysis of variance
(ANOVA) with the factors vehicle sessions (first vs.
second) and period (minutes 1–20, 21–40, and 41–60),
Table 1 Random-matched assignment based on body mass of 24 male minipigs to one of three groups, body mass (kilogram) at 36 weeks of age,
and the animals used (and doses administered) in the first and second d-amphetamine dose-finding experiments
Group Body mass (kg) at
group assignment
1st dose-finding experiment 2nd dose-finding experiment Reversal of the d-amphetamine-induced
behavioral activation
Doses of d-amphetamine
administered (mgkg−1)
Doses of d-amphetamine
administered (mgkg−1)
1st
testing
2nd
testing
Pig assigned to pair
number (1—12)
Order of testing
the pairs
1 12.7 Vehicle (0), 0.4 Vehicle Amph 2 4
13.3 Vehicle (0), 0.4, 0.7, 1, 2 Amph Vehicle 1 1
14.5 Vehicle (0), 0.2 (a) Vehicle Amph 4 10
15.4 Vehicle (0), 0.2 Amph Vehicle 3 7
16.0 Vehicle (0), 0.4 Vehicle Amph 4
17.1 Vehicle (0), 0.4 Amph Vehicle 3
17.6 Vehicle (0), 0.4, 0.7, 1, 2 Vehicle Amph 2
18.2 Vehicle (0), 0.2 Amph Vehicle 1
Mean ± SEM, 15.6±0.7
2 11.7 Vehicle (0), 0.2 Vehicle Amph 6 8
13.2 Vehicle (0), 0.4, 0.7, 1, 2 (b) Amph Vehicle 5 5
14.4 Vehicle (0), 0.2 Amph Vehicle 8 2
14.6 Vehicle (0), 0.4 Vehicle Amph 7 11
15.8 Vehicle (0), 0.2 Amph Vehicle 8
16.9 Vehicle (0), 0.2 Vehicle Amph 6
18.1 Vehicle (0), 0.4, 0.7, 1, 2 Vehicle Amph 7
18.4 Vehicle (0), 0.4 Amph Vehicle 5
Mean ± SEM, 15.4±0.8
3 12.2 Vehicle (0), 0.4 Amph Vehicle 11 6
13.6 Vehicle (0), 0.4, 0.7, 1, 2 Amph Vehicle 10 12
13.8 Vehicle (0), 0.2 Vehicle Amph 12 3
14.8 Vehicle (0), 0.4 Vehicle Amph 9 9
15.7 Vehicle (0), 0.4 Vehicle Amph 9
17.0 Vehicle (0), 0.2 Amph Vehicle 10
17.8 Vehicle (0), 0.4, 0.7, 1, 2 Vehicle Amph 12
18.8 Vehicle (0), 0.4 Amph Vehicle 11
Mean ± SEM, 15.5±0.8
Pigs from the same litter were assigned to different treatment groups. The three groups were randomly assigned to the treatment conditions in the
experiments assessing the effects of reference antipsychotics on d-amphetamine-induced behavioral activation in the OF. Within treatment groups,
pigs were randomly assigned to pairs. Pigs of a pair were tested in parallel in the two OFs. The order of testing the pairs of pig was randomized
and is shown in the last column
Haloperidol experiment—group 1: vehicle of haloperidol; group 2: 0.01 mg kg−1 haloperidol; group 3: 0.04 mg kg−1 haloperidol
Risperidone experiment—group 1: 0.01 mg kg−1 risperidone; group 2: 0.04 mg kg−1 risperidone; group 3: vehicle of risperidone
(a) This pig was crippled and had to be replaced by pig (b) [pig received 0.2 mg kg−1 d-amphetamine; vehicle data are from the second vehicle
session of pig (b), obtained in the first dose-finding experiment]
Amph amphetamine
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using the SAS GLM procedure. Then, the effects of
d-amphetamine on behavior in the OF were analyzed
statistically with a repeated measures ANOVA (Cotton
1998; Winer 1971) with the within-subject factors dose (0,
0.4, 0.7, 1, and 2 mg kg−1 d-amphetamine) and period
(minutes 1–20, 21–40, and 41–60), using the SAS GLM
procedure. For this analysis, the second vehicle control
session was taken as the drug-free baseline.
Analysis of the three successive 20-min periods (data not
shown) revealed that the effects of d-amphetamine were most
pronounced in the last 20-min period. Therefore, we
re-analyzed the video data of the third 20-min period using
a within-subjects ANOVA with the repeated measures factor
dose (0, 0.4, 0.7, 1, and 2 mg kg−1 d-amphetamine). This
analysis was complemented with contrasts. The first series of
contrasts was between the doses of 0.4, 0.7, 1, and
2 mg kg−1 and vehicle control, in order to determine at
which dose(s) of d-amphetamine the behavior of the pigs
deviated from the baseline (vehicle) measurement. The
second series of contrasts compared the successive doses
(0–0.4 mg kg−1; 0.4–0.7 mg kg−1; 0.7–1.0 mg kg−1; 1.0–
2.0 mg kg−1 d-amphetamine), in order to determine at which
of the increasing dose(s) of d-amphetamine OF behavior was
affected. The SAS GLM procedure, PROFILE contrasts, was
used.
Results
Reproducibility
Comparison of the OF behavior in the first and second
vehicle sessions confirmed that the OF behavior was highly
reproducible (all F values for vehicle sessions and for the
periods by vehicle sessions interaction: NS). The activity of
the pigs decreased across the three successive observation
periods (periods: all Fs2, 10>5.51, p<0.02; Fig. 2a–e),
indicating intra-session habituation.
Effects of amphetamine
As mentioned above, the effects of amphetamine on OF
behavior were studied in the last 20-min observation
period, when vehicle-treated pigs were the least active.
Distance moved (centimeter) d-Amphetamine treatment
tended to increase the distance moved (dose: F4, 20=2.81,
0.10>p>0.05). However, contrasts between the vehicle
control and increasing doses of d-amphetamine confirmed
that the 0.4-mg kg−1 dose of amphetamine increased the
distance moved, and only tended to increase the distance
moved with the two higher doses (0.7 and 1 mg kg−1
d-amphetamine; see Fig. 3a).
Mean velocity (centimeter per second) d-Amphetamine
affected movement velocity (dose: F4, 20 = 3.45,
p<0.0268) at the doses of 0.4 and 0.7 mg kg−1, as
confirmed by analysis of contrasts (see Fig. 3b).
Bouts of moving While ANOVA did not show d-
amphetamine to increase the number of bouts of moving
Fig. 2 Reproducibility of the OF data. The OF behavior of minipigs
during two vehicle control sessions of experiment 1 (within-subjects
design; n=6) and of two groups of minipigs in the vehicle control
session of experiment 2 (between-subjects design; n=9 per group) is
shown. The distance moved (centimeter; a), mean velocity (centimeter
per second; b), bouts of moving (c), total duration of moving (second;
d), and mean duration of moving per bout (second; e) are depicted as
means and standard errors of the means (SEM) for three successive
20-min periods. Note that the pigs used in experiment 1 were not used
in experiment 2
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(dose: F4, 20=1.56, NS), contrasts between vehicle and the
increasing doses of d-amphetamine showed that all doses
of d-amphetamine (except 2 mg kg−1) increased the bouts
of moving (see Fig. 3c).
Total duration of moving (second) d-Amphetamine
increased the time spent moving (dose: F4, 20=3.10,
p<0.0386). This effect was confirmed for the dose of
0.4 mg kg−1 d-amphetamine by analysis of contrasts (see
Fig. 3d).
Mean duration of moving per bout (second) The mean
duration of moving per bout was affected by d-amphetamine
(dose: F4, 20=5.45, p<0.0039), with the highest dose
(2 mg kg−1) decreasing the mean duration of moving
per bout, whereas lower doses were ineffective (see
Fig. 3e).
Behavioral observations
The behavior of the minipigs was scored, using the ethogram
published by Lind et al. (2005a), for three treatment
conditions: vehicle control and 0.7 (the dose used by Lind
et al. 2005a) and 2.0 mg kg−1 d-amphetamine (t statistics on
the difference scores between the vehicle and the d-
amphetamine treatment conditions, i.e., paired comparisons
with df=5; see Fig. 4). Only the behaviors that were affected
by d-amphetamine during at least one of the six 2-min
observation periods of a session are shown.
The highest dose of 2 mg kg−1 d-amphetamine
suppressed measures of OF exploration and activity,
whereas 0.7 mg kg−1 d-amphetamine increased it (e.g.,
Fig. 4d), in particular in the second half of the OF session.
d-Amphetamine did not induce stereotypic behavior.
Because direct observation appeared to be relatively
insensitive in detecting d-amphetamine-induced behavior,
automatic video-tracking, with EthoVision, was used in
the rest of the experiments.
Experiment 2: Assessment of the effects of 0.2
and 0.4 mg kg−1 d-amphetamine on OF behavior
The effects of d-amphetamine found in the previous
experiment were generally due to differences between the
lowest dose tested and both the highest dose tested and the
vehicle control condition. There were no clear effects of d-
amphetamine according to the ANOVAs performed. The
results suggested that the lowest dose tested (0.4 mg kg−1)
caused the most pronounced behavioral activation. Because
the dose-finding study was based on only six animals, we
repeated the experiment with two groups of nine minipigs,
using doses of 0.4 and 0.2 mg kg−1 d-amphetamine. The 18
drug-naïve pigs from the original batch of 24 animals were
used 9 weeks after conclusion of experiment 1 (see Table 1).
They were randomly assigned (SAS PLAN procedure) to the
treatment orders and d-amphetamine doses. The pigs were
first assigned to the 0.2- or 0.4-mg kg−1 d-amphetamine
treatment and then to one of the two different testing orders
Fig. 3 Effects of d-amphetamine on the OF behavior of minipigs during
the third 20-min observation period. d-Amphetamine at the dose of 0.4,
0.7, 1, or 2 mg kg−1, or its vehicle was injected s.c., immediately before
observations in the OF started. The distance moved (centimeter; a), mean
velocity (centimeter per second; b), bouts of moving (c), total duration of
moving (second; d), and mean duration of moving per bout (second; e)
are depicted as means and standard errors of the means (SEM)
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(vehicle session–washout period–d-amphetamine session, or
d-amphetamine session–washout period–vehicle session).
Unfortunately, one of the pigs assigned to the 0.2-mg kg−1
d-amphetamine condition was crippled and had to be
replaced by a pig that had already been used in the previous
dose-finding experiment (see Table 1). The data of the
second vehicle session of the first dose-finding experiment
for this pig were used as its control values. The OF behavior
of all pigs was video-tracked online using EthoVision. Two
pigs were tested in parallel.
Statistical analysis
The data for the two OFs and for the two testing orders were
pooled. In order to assess the reproducibility of results, the OF
behavior of the two groups of minipigs during the
amphetamine-free sessions was compared by a repeated
measures ANOVA (Cotton 1998; Winer 1971) with the
factors dose group (0.2, 0.4 mg kg−1 d-amphetamine) and
periods (minutes 1–20, 21–40, and 41–60 of the 60-min OF
test), using the SAS GLM procedure.
Fig. 4 a–h Effects of 0.7 and 2mg kg−1 d-amphetamine on OF
behavior of minipigs. Black symbols indicate a difference from vehicle
control (p<0.05, paired comparison t tests vs. vehicle). The
d-amphetamine effects were assessed using a within-subjects design,
i.e., each of the six pig was tested under all dose conditions
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The effect of d-amphetamine was most pronounced in
the third 20-min OF period (data not shown). Therefore,
we analyzed the effects of the two doses of d-amphetamine
in the last 20-min observation period by an ANOVA
with the repeated measures factor session (vehicle vs.
d-amphetamine session), and the between-subjects factor
dose (0.2 vs. 0.4 mg kg−1 d-amphetamine). The effects of
each dose of d-amphetamine were, in addition, evaluated
by calculating the difference scores between the d-
amphetamine and the vehicle sessions. The difference
scores (delta values) were subjected to one-sample t
statistics (with df=8).
Results
Reproducibility
Comparison of the OF behavior of the two groups after
administration of vehicle showed the results to be highly
reproducible (all F values for the dose group and for the
interaction of periods by the dose group <1.00, NS). Within
sessions, the activity of the pigs decreased across the three
observation periods on all measures (periods: all Fs2, 32>
21.50, p<0.0001; Fig. 2a–e).
Effects of amphetamine
Distance moved (centimeter) d-Amphetamine increased
the distance moved (session: F1, 16=24.11, p<0.0002),
but there was no difference between the two doses (dose:
F1, 16=1.69, NS; dose by session interaction: F1, 16=1.94,
NS). One-sample t statistics on the difference scores
revealed that 0.2 and 0.4 mg kg−1 d-amphetamine
increased the distance moved (see Fig. 5a).
Mean velocity (centimeter per second) The minipigs moved
faster after amphetamine (session: F1, 16=23.97, p<
0.0002), but there was no difference between the two doses
(dose: F1, 16=1.69, NS, dose by session interaction: F1, 16=
1.95, NS). One-sample t statistics on the difference scores
revealed that the mean velocity in the OF was increased
after treatment with 0.2 and 0.4 mg kg−1 d-amphetamine
(see Fig. 5b).
Bouts of moving d-Amphetamine treatment increased the
number of bouts of moving (session: F1, 16=41.11, p<
0.0001), an effect that appeared to be independent of the
dose administered (dose: F1, 16=2.06, NS; dose by
session interaction: F1, 16=1.01, NS). One-sample
t statistics on the difference scores revealed that both
doses of d-amphetamine treatment increased the number
of bouts of moving in the OF (see Fig. 5c).
Total duration of moving (second) Minipigs moved around
for longer after amphetamine (session: F1, 16=22.92, p<
0.0002), but this was not dose-dependent (dose: F1, 16=
1.24, NS, dose by session interaction: F1, 16=3.02, NS).
One-sample t statistics on the difference scores revealed
Fig. 5 Effects of 0.2 and 0.4 mg kg−1 d-amphetamine on the OF
behavior of minipigs. d-Amphetamine or its vehicle was injected s.c.,
immediately before observations in the OF started. The distance
moved (centimeter; a), mean velocity (centimeter per second; b),
bouts of moving (c), total duration of moving (second; d), and mean
duration of moving per bout (second; e) are depicted as means and
standard errors of the means (SEM) of the last 20-min period of the
OF test
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that the time spent moving increased after 0.2 and
0.4 mg kg−1 d-amphetamine (see Fig. 5d).
Mean duration of moving per bout (second) The mean
duration of moving per bout was unaffected by d-
amphetamine treatment (session: F1, 16=0.27, NS; dose:
F1, 16=0.04, NS; session by dose interaction: F1, 16=1.69,
NS; see Fig. 5e).
In summary, the minipigs appeared to have a stable
pattern of behavior in the OF, alternating between
standing still and short, forward movements. While the
duration of these bouts of moving was unaffected by
either dose of d-amphetamine, the distance moved, the
velocity of moving, the bouts of moving, and the total
duration of moving in the OF were increased by both
doses of d-amphetamine. Because the absolute effect size
appeared to be larger for 0.4 mg kg−1 d-amphetamine, the
remaining two experiments were performed with this dose.
Experiments 3 and 4: Reversal
of d-amphetamine-induced behavioral activation
in the OF by the antipsychotic compounds
haloperidol and risperidone
The ability of the antipsychotic compounds haloperidol and
risperidone to antagonize the d-amphetamine (0.4 mg kg−1)-
induced behavioral activation in the OF was tested. Three
groups of eight minipigs (one vehicle and two dose groups)
were tested twice, once after injection of the d-amphetamine
vehicle and once after injection of 0.4 mg kg−1 d-
amphetamine. The minipigs were assigned to groups on the
basis of body mass when they were about 36 weeks old (see
Table 1), and then, they were randomly assigned per group to
one of four pairs. The treatment order was randomly
determined per pair of pigs (first testing/second testing),
and the order of testing of the pairs was determined by
random permutation of the three treatment groups. All
randomizations were performed using the SAS PLAN
procedure. An animal was never tested more than twice a
week. The inter-test session interval, i.e., washout period,
was never less than 3 days. Videotaping and analysis of OF
behavior was performed as described above.
Statistical analysis The data of the third 20-min OF period
were analyzed using a two-factorial repeated measures
ANOVA (Cotton 1998; Winer 1971) with dose (vehicle,
low dose, high dose) of the antipsychotic drugs (haloperidol,
risperidone) as between-subjects factor and d-amphetamine
(vehicle, 0.4 mg kg−1 d-amphetamine) as within-subjects
factor. In addition, the effects of the two doses of the
antipsychotics on the effects of d-amphetamine were
assessed by an ANOVA on the difference (delta) between
the d-amphetamine session and the d-amphetamine vehicle
session, followed by Fisher’s least significant difference
(LSD) pairwise comparisons between the three groups
treated with different doses of the antipsychotic drug. The
delta values are indices of the size of the effect of
d-amphetamine.
The effects of haloperidol and risperidone on the OF
behavior of the minipigs were assessed in an ANOVA
with the factor dose; this analysis was based on the data
from the d-amphetamine vehicle sessions. The analyses
were supplemented with Fisher’s post hoc LSD compar-
isons between dose groups, where appropriate.
Experiment 3: Results (haloperidol)
Distance moved (centimeter) d-Amphetamine tended to
increase the distance moved in the OF (F1, 21=4.30, p<
0.0506). Haloperidol decreased the distance moved (F2, 21=
8.56, p<0.0019), a finding that was confirmed by analysis of
the d-amphetamine-free sessions (haloperidol: F2, 21=5.38,
p<0.0139). The ANOVA failed to detect an interaction
between the effects of the two compounds (d-amphetamine
by haloperidol interaction: F2, 21=2.10, NS). However,
because visual inspection of Fig. 6a suggested that haloper-
idol dose-dependently antagonized the d-amphetamine-
induced increase of distance moved in the OF, we
performed a post hoc analysis. This analysis revealed that
the high dose of haloperidol strongly decreased the distance
moved compared with the vehicle control group, whereas the
distance moved of the group treated with the low dose of
haloperidol was intermediate between the vehicle group and
the group treated with the high dose and did not differ from
either.
Mean velocity (centimeter per second) Treatment with
d-amphetamine tended to increase the mean velocity
(F1, 21=4.14, 0.10>p>0.05). Haloperidol decreased the
mean velocity dose dependently (F2, 21=8.54, p<0.0019).
This effect was confirmed in a separate ANOVA of the
d-amphetamine-free sessions (haloperidol: F2, 21=5.04,
p<0.0163). There was no interaction between the effects
of the d-amphetamine and haloperidol (F2, 21=2.13, NS).
However, post hoc comparisons confirmed the impression
that the group of minipigs treated with the high dose of
haloperidol (0.04 mg kg−1) moved around slower than the
vehicle-treated group, whereas the group treated with the low
dose (0.01 mg kg−1) moved at a speed intermediate between
that of the vehicle group and the high-dose haloperidol
group, and did not differ from both (see Fig. 6b).
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Fig. 6 Effects of 0.4 mg kg−1 d-amphetamine and the reference
antipsychotics haloperidol (0.01 or 0.04 mg kg−1; first and second
rows, a–e) and risperidone (0.01 or 0.04 mg kg−1; third and fourth
rows, f–j) on the OF behavior of minipigs. d-Amphetamine or its
vehicle was injected s.c., immediately before observations in the OF
started. The reference antipsychotic or its vehicle was injected s.c.
approximately 30 min before the minipigs were tested in the OF. For
each of the two reference antipsychotics, the distance moved
(centimeter), mean velocity (centimeter per second), bouts of moving,
total duration of moving (second), and mean duration of moving per
bout (second) are depicted as means and standard errors of the means
(SEM) of the last 20-min period of the OF test
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Bouts of moving d-Amphetamine increased the number of
bouts of moving (F1, 21=5.37, p<0.0307). Haloperidol
decreased this measure (F2, 21=5.39, p<0.0129), as
confirmed by analysis of the d-amphetamine-free sessions.
Haloperidol tended to affect the d-amphetamine-induced
increase of the number of bouts of moving differentially
(d-amphetamine by haloperidol interaction: F2, 21=2.76,
0.10>p>0.05). However, separate ANOVA on the d-
amphetamine-free sessions did not confirm this finding
(haloperidol: F2, 21=1.65, NS), and subsequent post hoc
comparisons did not detect differences between the
different doses of haloperidol (see Fig. 6c).
Total duration of moving (second) d-Amphetamine treat-
ment increased the total duration of moving (F1, 21=7.10,
p<0.0145), whereas haloperidol decreased this measure
(F2, 21=8.68, p<0.0018). The haloperidol effect was also
confirmed in the separate analysis that was restricted to the
d-amphetamine-free sessions (haloperidol: F2, 21=4.62, p<
0.0217). Haloperidol did not differentially affect the
d-amphetamine-induced increase of the total duration of
moving (d-amphetamine by haloperidol interaction: F2, 21=
2.47, NS). Visual inspection of Fig. 6d suggested that
haloperidol antagonized the d-amphetamine-induced
increase in total duration of moving dose dependently. This
impression was supported by post hoc comparisons:
treatment with 0.04 mg kg−1 haloperidol decreased the
total duration of moving compared with the vehicle-treated
group. The group treated with 0.01 mg kg−1 haloperidol
spent time moving in the OF intermediate between the
vehicle group and the high-dose group. The low dose group
did not differ from the two other groups on this measure
(see Fig. 6d).
Mean duration ambulating per bout (second) d-Amphetamine
did not affect the mean duration ambulating per bout
(F1, 21=0.00, NS). Haloperidol treatment caused a decrease
of this measure (F2, 21=6.53, p<0.0063). This result was
only weakly confirmed by analysis of the d-amphetamine-
free sessions (haloperidol: F2, 21=2.86, 0.10>p>0.05).
There was no interaction between the effects of d-
amphetamine and haloperidol (F2, 21=0.11, NS; see Fig. 6e).
Experiment 4: Results (risperidone)
Distance moved (centimeter) d-Amphetamine increased the
distance moved in the OF (F1, 21=9.69, p<0.0053).
Risperidone decreased the distance moved (F2, 21=12.32,
p<0.0003), a finding that was confirmed by analysis of the
d-amphetamine-free sessions (risperidone: F2, 21=5.37, p<
0.0131). Although there was no interaction between the
effects of d-amphetamine and risperidone (F2, 21=2.10,
NS), visual inspection of Fig. 6f suggested that risperidone
dose dependently antagonized the effects of d-amphetamine
on the distance moved. Post hoc analysis confirmed that the
high dose of risperidone strongly decreased the distance
moved compared with the vehicle control group, and the
group treated with the low dose of risperidone, which did
not differ from one another (see Fig. 6f).
Mean velocity (centimeter per second) Treatment with
d-amphetamine increased the mean velocity (F1, 21=9.75,
p<0.0051). Risperidone decreased the mean velocity (F2, 21=
12.44, p<0.0003). This effect was confirmed in a separate
ANOVA on the d-amphetamine vehicle sessions (risperi-
done: F2, 21=5.25, p<0.0138). Treatment with risperidone
tended to affect the effects of d-amphetamine differentially
(d-amphetamine by risperidone interaction: F2, 21=2.60,
0.10>p>0.05). Post hoc comparisons confirmed that the
group of minipigs treated with the high dose of risperidone
(0.04 mg kg−1) moved around in the OF with a lower speed
than the vehicle-treated group and the group treated with the
low dose of risperidone (0.01 mg kg−1). The latter two
groups did not differ from one another (see Fig. 6g).
Bouts of moving The number of bouts of moving increased
after d-amphetamine treatment (F1, 21=23.74, p<0.0001),
whereas risperidone decreased this measure (F2, 21=17.90,
p<0.0001). Separate ANOVA on the d-amphetamine
vehicle sessions confirmed this finding (risperidone: F2, 21=
5.07, p<0.0160). Risperidone dose dependently antagonized
the d-amphetamine-induced increase of the number of bouts
of moving (d-amphetamine by risperidone interaction: F2, 21=
11.53, p<0.0004). Subsequent post hoc comparisons revealed
that the high dose of risperidone decreased the number of
bouts of moving compared with the control condition. In the
group treated with the low dose of risperidone, the number of
bouts was intermediate between that of the two other groups
(see Fig. 6h).
Total duration of moving (second) d-Amphetamine treat-
ment increased the total duration of moving (F1, 21=
10.03, p<0.0046), whereas risperidone decreased the total
duration of moving (F2, 21=15.28, p<0.0001). This effect
of risperidone was also confirmed in the separate ANOVA
that was restricted to the d-amphetamine-free sessions
(risperidone: F2, 21=4.72, p<0.0203). Risperidone dose
dependently antagonized the d-amphetamine-induced
increase in total duration of moving (d-amphetamine by
risperidone interaction: F2, 21=5.25, p<0.0140). Post hoc
comparisons confirmed that treatment with 0.04 mg kg−1
risperidone decreased the total duration of moving
compared with the vehicle-treated group and the group
treated with 0.01 mg kg−1 risperidone; these two groups
did not differ from one another (see Fig. 6i).
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Mean duration of moving per bout (second) Neither
d-amphetamine (F1, 21=0.76, NS) nor risperidone (F2, 21=
2.51, NS) affected the mean duration ambulating per
bout. The lack of effect of risperidone was confirmed
by analysis of the d-amphetamine vehicle sessions (ris-
peridone: F2, 21=1.72, NS). There was no interaction
between the effects of d-amphetamine and risperidone (d-
amphetamine by risperidone interaction: F2, 21=1.05, NS;
see Fig. 6j).
Body mass Analysis of variance with the factor group
(groups 1 to 3; see Table 1) and the repeated measures factor
age (36, 49, 53, 64, 68, and 72 weeks of age) showed that
the groups of minipigs were of similar body mass (36-week-
old: F2, 21=0.02, NS; 49-week-old: F2, 21=0.69, NS;
53-week-old: F2, 21=0.83, NS; 64-week-old: F2, 21=1.25,
NS; 68-week-old: F2, 21=0.74, 72-week-old: F2, 21=0.49,
NS; general mean, i.e., average across all time points:
F2, 21=0.61, NS), and that the three groups gained weight
at a similar rate (age: F5, 105=753.27, p<0.0001; group by
age interaction: F10, 105=0.91; NS; see Fig. 7).
Discussion
Pigs have a highly developed central nervous system and
their physiology, pharmacokinetics, and genetics are similar
to those of humans (Larsen and Rolin 2004). Given these
similarities, we expected that minipigs would be a useful
model that closes the gap between preclinical drug testing
in rodents and clinical testing in humans (de Groot et al.
2005; Lind et al. 2007; Nunoya et al. 2007; Vodička et al.
2005). We investigated whether the d-amphetamine-treated
pig could serve as an animal model for testing the
antipsychotic-like actions of compounds. To this end, we
first determined the lowest dose of d-amphetamine
(0.4 mg kg−1) that reliably induced activation in the OF
without inducing obvious side effects and used this dose to
determine whether the antipsychotics haloperidol and
risperidone could antagonize the d-amphetamine-induced
OF activation.
Reproducibility of open-field behavior in minipigs
Analyses assessing the reproducibility of the OF behavior
of the minipigs, using both a within-subjects design and a
between-subjects design, showed that the OF behavior of
the minipigs was highly reproducible when tested after
administration of the vehicle.
Methodological considerations
Group size Although six Göttingen minipigs per group
were used in the first dose-finding study, results were more
robust when nine minipigs were used per group in the
second dose-finding study. Larger groups may increase the
sensitivity to detect interactions between the effects of
d-amphetamine and of clinically applied or putative novel
antipsychotics.
Direct observations based on the extended Lind ethogram We
found that assessment of the effects of d-amphetamine on OF
behavior by direct observation, using a published ethogram
(Lind et al. 2005a), was time- and resource-consuming and
rather insensitive to detect d-amphetamine-induced changes
in OF behavior. In contrast, the video-tracking method was
sensitive enough to reproducibly detect the effects of low
doses of d-amphetamine. Our findings confirm and extend
the observations of Lind and colleagues, who investigated
the effects of 0.7 mg kg−1 d-amphetamine on the OF
behavior of Göttingen minipigs (Lind et al. 2005a).
Habituation of vehicle groups Despite extensive habitua-
tion to the test setup in the days preceding testing, a strong
within-session habituation effect was detected in the
vehicle-treated groups, with decreasing activity seen over
the three successive 20-min periods (see Fig. 2). This
decrease in activity in the vehicle group increased the
difference between d-amphetamine- and vehicle-treated
groups. Longer habituation times on the test day itself,
prior to injection may help to improve future experiments.
d-Amphetamine dose-finding experiments
The effects of d-amphetamine on the OF behavior of
Göttingen minipigs were assessed in two experiments. The
maximal increase in OF behavior was 50%, elicited with
0.4 mg kg−1 amphetamine. A lower, but not higher, dose also
Fig. 7 Average body mass (kilogram) and standard error of the mean
(SEM) of minipigs that were allocated to three different treatment
groups by random matched assignment, based on their weights at the
age of 36 weeks. The composition of the three groups is shown in
Table 1. Note that the stable increase in body mass in the three groups
of minipigs continued beyond the age at which the last experiment of
the present study was performed
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affected the pigs’ OF behavior, but the absolute effect sizes
were smaller than those found with 0.4 mg kg−1
d-amphetamine, and they emerged later during the 1-h OF
sessions (data not shown). It is worth noting that the 50%
maximum increase in OF behavior is much smaller than that
elicited by d-amphetamine in rats (nearly 2,000%; Nordquist
et al. 2008b) and mice (350%; Nordquist et al. 2008a). The
dose–response curve may be shifted to the right in rodents,
and the effective dose range in rats appears to be wider than
that observed in minipigs (Grilly and Loveland 2001).
Interestingly, the dose of 0.4 mg kg−1 is also identical to
that shown to induce restlessness in non-human primates
(Peacock and Gerlach 1999; Peacock et al. 1999). The few
studies that have reported on amphetamine-induced locomo-
tion in humans have reported very little effect or decreased,
rather than increased, locomotion (Grilly and Loveland
2001). We found a decrease at the highest dose tested
(2 mg kg−1 body mass), which could suggest that high doses
cause motor side effects. Psychostimulant-induced locomo-
tion is considered a model of psychostimulant-induced
psychosis in humans. In a study of patients who had
experienced a single psychotic episode, a single dose of
18 mg of amphetamine increased scores on the Brief
Psychotic Rating Scale. Assuming an average weight of
70 kg, this translates to 0.26 mg kg−1. Our results may
indicate that the relatively modest increase in locomotion
induced by amphetamine in minipigs better reflects the
effects of amphetamines on human and non-human primate
behavior than the large increase in locomotion elicited by
amphetamine in rodents.
Effects of the antipsychotic compounds haloperidol
and risperidone on OF behavior
We found that both haloperidol (0.04 mg kg−1) and
risperidone (0.04 mg kg−1) decreased spontaneous locomo-
tor activity (distance moved, mean velocity, and total
duration of moving). Lind et al. also reported a decrease
in OF activity in pigs after administration of 0.2 mg kg−1
haloperidol (Lind et al. 2005a). By comparison, haloperidol
decreased activity in rats at 0.08 mg kg−1 s.c., but not at
0.04 mg kg−1 s.c., and risperidone decreased spontaneous
locomotion at 0.62 mg kg−1 s.c., but not at 0.18 mg kg−1 s.
c. (Bardin et al. 2007). Thus, the doses of haloperidol and
risperidone that inhibited spontaneous locomotion were
lower in minipigs than in rodents. This may indicate that
minipigs are more sensitive to antipsychotics, but this needs
to be substantiated in pharmacokinetic studies. One of the
few studies to examine the effects of acute dosing of
antipsychotics on locomotion in healthy humans demon-
strated a lack of effect of haloperidol at a dose of 2 mg p.o.,
the only dose tested (Kiang et al. 2003). The weight of the
subjects was not reported, but assuming an average weight of
70 kg, a single dose of 2 mg p.o. translates to 0.03 mg kg−1
p.o., a dose that would not be expected to produce locomotor
suppression on the basis of pig or rat data. However, the
effective doses in our study are within the range used for
human dosing, i.e., 0.5–2 mg per dosing for haloperidol,
which translates to approximately 0.01–0.03 mg kg−1 and
4–8 mg b.i.d. for risperidone, which translates to 0.03–
0.05 mg kg−1 per dose (for FDA dosing information about
oral haloperidol and risperidone, see http://dailymed.nlm.nih.
gov/dailymed/drugInfo.cfm?id=7211 and http://dailymed.
nlm.nih.gov/dailymed/drugInfo.cfm?id=6159, respectively).
Effects of haloperidol and risperidone
on the d-amphetamine-induced behavioral activation
in the OF
Haloperidol tended to and risperidone did dose depen-
dently antagonize the behavioral activation induced by d-
amphetamine (0.4 mg kg−1). The high dose (0.04 mg kg−1)
of both antipsychotics fully antagonized whereas the low
dose (0.01 mg kg−1) only partially antagonized the effects
of d-amphetamine for all parameters measured with the
exception of mean duration of moving, which was not
affected by amphetamine. Studies of rats have reported
reversal of amphetamine (0.63 mg kg−1)-induced hyper-
locomotion by haloperidol and risperidone, with an ED50
of 0.09 mg kg−1 s.c. haloperidol and 0.14 mg kg−1 s.c.
risperidone (Bardin et al. 2007). Although no minimum
effective doses are listed, the 0.04-mg kg−1 dose used as
the high dose in the present study is at the low end of the
95% confidence intervals in the study by Bardin et al
(0.04–0.17 mg kg−1 and 0.03–0.56 mg kg−1 for haloper-
idol and risperidone, respectively). The 0.04-mg kg−1 dose
is on the low end of this confidence interval, but the dose of
d-amphetamine used to induce hyperlocomotion was also
higher than in the present study. Taken together, these data
indicate that the minimal effective dose for attenuation/
reversal of d-amphetamine-induced activity is similar in pigs
and rats. Moreover, the 0.01-mg kg−1 dose of haloperidol,
which was active in the present study, is in the range of
doses used in non-human primates (0.015 mg kg−1 s.c.) for
reversal of d-amphetamine-induced behavior (Peacock and
Gerlach 1999). This dose is ineffective in suppressing loco-
motion in rodents. This supports the closer pharmacological
homology between minipigs and primates than between
rodents and primates, further supporting the putative transla-
tional relevance of minipigs for pharmacological studies.
Conclusions
In conclusion, d-amphetamine at a dose of 0.4 mg kg−1
body mass induced a specific pattern of locomotor activity
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in male Göttingen minipigs. This effect on locomotor
activity in the OF was (dose dependently) attenuated by
haloperidol and risperidone. In addition, both antipsy-
chotics dose dependently reduced spontaneous locomotor
activity in the OF.
The d-amphetamine-induced behavioral activation of
minipigs may be a valuable animal model for testing the
efficacy of novel putative antipsychotics and may be
considered as an alternative to the use of non-human
primates.
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